Answers are grounded in this paper and cite their sources.
Oxidized graphene quantum dots (o-GQDs) alter viability and cell-cycle progression in breast cancer cells, yet the cellular programs underlying these effects remain incompletely defined. We exposed MCF-7 cells to 10 mg/L o-GQD for 72 h and integrated RNA sequencing with quantitative protein-marker, ROS, antioxidant-intervention, proteasome-inhibition, and puromycin-labeling analyses from independent experiments. Transcriptomic analyses showed significant negative enrichment of proliferative and cell-cycle programs (E2F Targets, G2M Checkpoint, MYC Targets V1), with complementary KEGG/Reactome evidence of attenuated estrogen-associated programs. Quantitative Western blotting showed dose-dependent reductions in ERα (to 41.36 ± 13.73% at 10 mg/L), p-RB (to 8.31 ± 10.39%), and Survivin (to 23.97 ± 19.01%), with p-ERK/ERK attenuation and marked γ-H2AX accumulation (345.21 ± 161.39%). The ROS-positive fraction rose from 6.86% to 30.46%; antioxidant co-treatment failed to rescue the phenotype and MG132 did not consistently restore protein markers, arguing against oxidative stress or proteasomal degradation as standalone drivers. Reduced puromycin labeling added a protein-homeostasis readout consistent with reduced nascent protein synthesis. BT-474 and MDA-MB-231 cells showed weaker or different marker responses. Together, these findings define a coordinated MCF-7 response spanning estrogen-associated and cell-cycle programs, survival markers, protein homeostasis, and cell fate.
No takes yet. Share an insight, caveat, or question.
Shia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: